A5078363282- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Synthesis and biological activity
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Marine Sponges and Natural Products
- Multiple Myeloma Research and Treatments
- Synthesis and Characterization of Heterocyclic Compounds
- Cancer Cells and Metastasis
- Microtubule and mitosis dynamics
- Cell Adhesion Molecules Research
- Protein Kinase Regulation and GTPase Signaling
- Cancer-related Molecular Pathways
- PI3K/AKT/mTOR signaling in cancer
- Glycosylation and Glycoproteins Research
- Cancer therapeutics and mechanisms
- Melanoma and MAPK Pathways
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- Chromatin Remodeling and Cancer
- Cancer, Hypoxia, and Metabolism
- Ubiquitin and proteasome pathways
- Radiopharmaceutical Chemistry and Applications
- Cancer Mechanisms and Therapy
- Spanish Literature and Culture Studies
Instituto de Investigación Biomédica de Salamanca
2018-2024
Centro de Investigación Biomédica en Red de Cáncer
2017-2024
Complejo Hospitalario de Salamanca
2022-2024
Universidad de Salamanca
2012-2024
Universidad de la República
2024
Centro de Investigación del Cáncer
2014-2023
Pontificia Universidad Católica del Ecuador
2022
Universidad de Sevilla
2022
Instituto de Salud Carlos III
2019
Hospital General Universitario de Albacete
2017
The ectodomain of certain transmembrane proteins can be released by the action cell surface proteases, termed secretases. Here we have investigated how mitogen-activated protein kinases (MAPKs) control shedding membrane proteins. We show that extracellular signal-regulated kinase (Erk) acts as an intermediate in C-regulated TrkA cleavage. report cytosolic tail tumor necrosis factor alpha-converting enzyme (TACE) is phosphorylated Erk at threonine 735. In addition, and TACE associate. This...
Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) compounds that promote protein degradation by binding to ubiquitin ligase. In this work, we explored the antitumoral activity of two BET-PROTACs, MZ1 and ARV-825, in TNBC, ovarian a BET inhibitor resistant model.OVCAR3, SKOV3, BT549, MDA-MB-231 cell lines JQ1 line MDA-MB-231R were evaluated. MTTs, colony-forming assay, three-dimensional cultures...
The four receptor tyrosine kinases of the ErbB family play essential roles in several physiological processes and have also been implicated tumor generation and/or progression. Activation ErbB1/EGFR is mainly triggered by epidermal growth factor (EGF) other related ligands, while activation ErbB2, ErbB3, ErbB4 receptors occurs binding to another set EGF-like ligands termed neuregulins (NRGs). Here we show that Erk5 mitogen-activated protein kinase (MAPK) pathway participates NRG signal...
Abstract Despite recent progress in its treatment, multiple myeloma (MM) remains incurable, thus necessitating identification of novel anti-MM agents. We report that the marine-derived cyclodepsipeptide Aplidin exhibits, at clinically achievable concentrations, potent vitro activity against primary MM tumor cells and a broad spectrum human cell lines, including resistant to conventional (e.g., dexamethasone, alkylating agents, anthracyclines) or thalidomide bortezomib) is active presence...
Background Breast cancer is the most common neoplasia in women. Even though advances its treatment have improved disease outcome, some patients relapse. Therefore, attempts to better define molecular determinants that drive breast cell proliferation may help defining potential therapeutic targets. Mitogen-activated protein kinases (MAPK) play important roles tumorigenesis. One of them, Erk5, has been linked cells vitro. Here we investigated expression and prognostic value Erk5 human cancer....
Abstract Background The androgen receptor (AR) plays a central role in the oncogenesis of different tumors, as is case prostate cancer. In triple negative breast cancer (TNBC) gene expression classification has described subgroups including luminal subtype. AR can be controlled by several mechanisms like activation membrane tyrosine kinases and downstream signaling pathways. However little known TNBC about how modulated these potential therapeutic strategists to inhibit its expression....
Abstract Ovarian cancer is characterized by frequent mutations at TP53. These tumors also harbor germline homologous recombination repair genes, so they rely on DNA-damage checkpoint proteins, like the kinase 1 (CHEK1) to induce G2 arrest. In our study, using an in silico approach, we identified a synthetic lethality interaction between CHEK1 and mitotic aurora A (AURKA) inhibitors. Gene expression analyses were used for identification of relevant biological functions. OVCAR3, OVCAR8,...
In the last few years, nivolumab has become standard of care for advanced-stage lung cancer patients. Unfortunately, up to 60% patients do not respond this treatment. our study, we identified variations in gene expression related primary resistance immunotherapy. Bronchoscopy biopsies were obtained from advanced non-small cell (NSCLC) previously characterized as responders or non-responders after Ten tumor (from three and seven non-responders) analyzed by differential 760 genes using...
mTOR is a serine/threonine kinase that acts by binding different sets of proteins forming two complexes, termed mTORC1 and mTORC2. deregulated in substantial proportion ovarian tumors. Despite the use drugs directed to ongoing clinical trials, functional relevance individual mTORC branches cancer not known. Here, we show mTORC2 were constitutively active cell lines. Knockdown raptor or rictor, required for function mTORC2, respectively, resulted profound inhibition proliferation. The...
// Antonio Garcia-Gomez 1,2,3 , Javier De Las Rivas 1 Enrique M. Ocio 1,2 Elena Díaz-Rodríguez Juan C. Montero Montserrat Martín 1,3 F. Blanco 2 Fermín Sanchez-Guijo 2,3 Atanasio Pandiella Jesús San Miguel and Mercedes Garayoa Centro de Investigación del Cáncer, IBMCC (Universidad Salamanca-CSIC), Salamanca, Spain Hospital Universitario Salamanca-IBSAL, 3 en Red Medicina Regenerativa y Terapia Celular Castilla León, Correspondence: Garayoa, email: Keywords : multiple myeloma, bone marrow...
Abstract The ligands of the epidermal growth factor family and their receptors, ErbB proteins, have been linked to development different types cancer. Particular attention has focused on ErbB2, whose activation may occur by receptor overexpression or ligand-induced oligomerization with other receptors. Whether these two modes ErbB2 cause same biological responses is unknown. Here, we uncovered important differences in signaling, proliferation rates, response anti-ErbB2 antibodies when...
Background Proteasome inhibition represents a promising novel anticancer therapy, and bortezomib is highly selective reversible inhibitor of the proteasome complex. Acute myeloid leukemia (AML) an immnunophenotypically heterogeneous group diseases, with CD34+ cases being associated drug resistance poor outcome. We investigated effects on growth survival AML cells.Design Methods studied in vitro activity mechanism action both cell lines fresh cells from 28 patients including CD34−...
Human epidermal growth factor receptor 2 (HER-2) overexpression has been associated with the genesis and progression of a subset breast cancers. The function HER-2 may be upregulated by or availability neuregulins (NRGs), group transmembrane factors. Transmembrane NRGs strongly activated cell proliferation in cancer cells that did not overexpress HER-2, treatment trastuzumab prevented proliferative action NRG. This raised relevant clinical question whether patients considered as negative,...
The receptor tyrosine kinase, HER2, is overexpressed in approximately 25% of patients with breast cancer and implicated the aggressiveness cancer. Targeting HER2 signaling trastuzumab, a monoclonal antibody that inhibits activity, has demonstrated clinical benefits.We investigated whether antitumor activity trastuzumab can be potentiated by dasatinib, small-molecule kinase inhibitor, on cell lines overexpress (BT474 SKBR3) or have normal expression (MCF7 T47D). Functional, biochemical, gene...